Notifications

Home

Stocks
- Stock Screener
- Market Movers
- Insider Trades
- Upcoming Earnings
- Upcoming Dividends
Options
- Unusual Options Activity
- Implied Volatility Rank
- Volatility %Change
News
Upcoming IPOs

Valion Bio Inc (VBIO)

$0.96 -0.05 (-4.95%)

Overview
Financial
Short Interest
Institutional Holdings
Dividends
Charts

Market Cap	N/A
Revenue (ttm)	N/A
Net Income (ttm)	N/A
EPS (ttm)	N/A
PE Ratio	0.00
Forward PE	N/A
Profit Margin	0.00%
Debt to Equity Ratio	0.00

Volume	71,900
Avg Vol	307,812
Day's Range	N/A - N/A
Shares Out	N/A
Stochastic %K	28%
Beta	N/A
Analysts	Strong Buy
Price Target	$3.50

VALION BIO BRIEFS PENTAGON LEADERSHIP ON ENTOLIMOD™ FOR ACUTE RADIATION SYNDROME

Apr 23, 2026, 4:05 PM EDT - 6 days ago

Tivic Health Systems Rebrands as Valion Bio, Reflecting Completed Transformation into a Late-Stage Biopharmaceutical Company with Government-Backed Asset and Potential Multiple Revenue Stream Model

Apr 15, 2026, 8:00 AM EDT - 14 days ago

Tivic Health Selected to Present Entolimod™ as a Radiation Countermeasure and its Plans for an Oral Transmucosal Program to the Department of War Tech Watch Program on May 7th

Apr 1, 2026, 2:55 PM EDT - 4 weeks ago

Valion Bio Transcript: Emerging Growth Conference 91

Mar 31, 2026, 8:30 AM EDT - 4 weeks ago

Tivic Receives Formal Request for Information from Ukrainian Ministry of Health Regarding Strategic Stockpiling of Entolimod

Mar 27, 2026, 11:30 AM EDT - 4 weeks ago

Tivic CEO To Present at the Upcoming Emerging Growth's April 2026 Virtual Conference

Mar 26, 2026, 8:30 AM EDT - 4 weeks ago

Tivic Secures NIAID Non-Clinical Evaluation Agreement for Entolimod, Targeting Gastrointestinal Acute Radiation Syndrome

Mar 25, 2026, 4:30 PM EDT - 5 weeks ago

Valion Bio Earnings Call Transcript: Q4 2025

Mar 25, 2026, 4:05 PM EDT - 5 weeks ago

Tivic Reports Full Year 2025 Results

Mar 24, 2026, 9:30 AM EDT - 5 weeks ago

Tivic Health CEO Letter to Shareholders

Mar 20, 2026, 3:35 PM EDT - 5 weeks ago

Tivic To Report 2025 Year-End Financial Results Via Conference Call and Webcast on March 25th at 1:30pm PT / 4:30pm ET

Mar 12, 2026, 4:00 PM EDT - 6 weeks ago

Valion Bio Transcript: EGM 2026

Mar 4, 2026, 8:30 AM EST - 2 months ago

Biotech Veteran Michael K. Handley Named CEO of Tivic Health Systems to Spearhead Strategic Expansion in Biopharma

Feb 18, 2026, 9:15 AM EST - 2 months ago

Tivic and BARDA Continue Discussions of Entolimod for Acute Radiation Syndrome on March 10

Jan 28, 2026, 8:30 AM EST - 3 months ago

Tivic, BARDA Discuss Entolimod(TM) for Acute Radiation Syndrome at TechWatch Meeting

Jan 26, 2026, 10:10 AM EST - 3 months ago

Tivic to Showcase Strategic Pivot and Forward Outlook on Advancing Entolimod(TM) to Commercialization at DealFlow Discovery Conference

Jan 22, 2026, 4:10 PM EST - 3 months ago

Valion Bio Transcript: Emerging Growth Conference 89

Jan 20, 2026, 5:50 PM EST - 3 months ago

Tivic CEO To Present at the Upcoming Emerging Growth's January 2026 Virtual Conference

Jan 12, 2026, 4:30 PM EST - 3 months ago

Valion Bio Transcript: Investor Update

Jan 12, 2026, 9:00 AM EST - 3 months ago

Tivic Delivers 200x Scale-up in Manufacturing for Lead Drug Candidate Entolimod(TM) And Achieves Reproducible Yields, Potency and Purity

Jan 8, 2026, 8:30 AM EST - 3 months ago

Tivic Announces Special Webcast To Discuss Its Recent Acquisition of CDMO Assets - Highlighting Near-Term Strategic Potential and Immediate Contributions to Accelerated Drug Development Timelines

Dec 11, 2025, 9:45 AM EST - 4 months ago

Tivic Acquires Ready-to-Scale cGMP Manufacturing and Development Assets to Accelerate Commercialization of Entolimod; Tivic Growth Backed By $90M+ Financing Package

Nov 18, 2025, 8:30 AM EST - 5 months ago

Tivic Secures Barda Meeting for Entolimod(TM) for Acute Radiation Syndrome

Nov 14, 2025, 4:30 PM EST - 5 months ago

Tivic Reports Third Quarter 2025 Financial Results

Nov 14, 2025, 4:30 PM EST - 5 months ago

Valion Bio Earnings Call Transcript: Q3 2025

Nov 13, 2025, 8:30 AM EST - 5 months ago

Tivic Health Reports Findings of Clinical Optimization Trial of Non-Invasive Cervical Vagus Nerve Stimulation (ncVNS)

Nov 10, 2025, 9:00 AM EST - 6 months ago

Tivic Expands Intellectual Property Portfolio

Nov 6, 2025, 9:30 AM EST - 6 months ago

Tivic Health to Report Third Quarter 2025 Financial Results on November 14th Via Conference Call and Webcast

Oct 22, 2025, 2:00 PM EDT - 6 months ago

Tivic CEO, Jennifer Ernst, to Join Panel at 8th Annual Northwell Health Innovation Constellation Forum on Thursday, Oct. 23

Sep 25, 2025, 11:25 AM EDT - 7 months ago

Valion Bio Transcript: Emerging Growth Conference 2025

Sep 22, 2025, 8:30 AM EDT - 7 months ago

Tivic Health CEO Jennifer Ernst to Present at Emerging Growth's September Virtual Conference

Sep 10, 2025, 8:30 AM EDT - 8 months ago

Tivic Completes Verification of Entolimod™ Cell Line: First Step in Establishing CGMP Manufacturing for BLA Filing

Aug 20, 2025, 8:30 AM EDT - 9 months ago

Tivic Receives Two Investigational New Drug Applications for Entolimod™ for the Treatment of Acute Radiation Syndrome (ARS) and Advanced Cancers

Aug 15, 2025, 8:30 AM EDT - 9 months ago

Tivic Health Advances Discussions on Use of Entolimod as a Radiation Countermeasure at Military Health System Research Symposium 2025

Aug 14, 2025, 4:30 PM EDT - 9 months ago

Valion Bio Earnings Call Transcript: Q2 2025

Aug 14, 2025, 4:00 PM EDT - 9 months ago

Tivic Reports Second Quarter 2025 Financial Results

Aug 7, 2025, 8:30 AM EDT - 9 months ago

Tivic Health to Report Second Quarter 2025 Financial Results on August 14th Via Conference Call and Webcast

Jul 8, 2025, 8:30 AM EDT - 10 months ago

Tivic Shareholders Approve Key Proposals in Support of Strategic Transformation; Lisa Wolf Appointed Permanent CFO

Jun 25, 2025, 8:30 AM EDT - 11 months ago

Tivic Health Completes Optimization Study for Its Non-Invasive Vagus Nerve Stimulation Device

Jun 24, 2025, 8:30 AM EDT - 11 months ago

Tivic Health Announces 2025 Annual Meeting of Stockholders

Jun 11, 2025, 1:30 PM EDT - 11 months ago

Valion Bio Transcript: Life Sciences Virtual Investor Forum

May 22, 2025, 1:00 PM EDT - 1 year ago

Valion Bio Transcript: Sidoti May Micro-Cap Virtual Conference

May 15, 2025, 4:30 PM EDT - 1 year ago

Valion Bio Earnings Call Transcript: Q1 2025

May 15, 2025, 4:05 PM EDT - 1 year ago

Tivic Reports First Quarter 2025 Financial Results and Provides Updates on Business Transformation

May 14, 2025, 8:30 AM EDT - 1 year ago

Tivic Health Enters GMP Manufacturing Validation Agreement with Scorpius BioManufacturing in Preparation for FDA Submission

May 13, 2025, 8:30 AM EDT - 1 year ago

Tivic Expands VNS Intellectual Property Portfolio

May 9, 2025, 8:30 AM EDT - 1 year ago

Tivic Health to Report First Quarter 2025 Financial Results on May 15th Via Conference Call and Webcast

Apr 22, 2025, 8:30 AM EDT - 1 year ago

Tivic Health Reports White House Briefing and FDA Meetings Secured Positive Interest in Potential Military and Defense Applications of Its Product Candidates

Apr 15, 2025, 8:30 AM EDT - 1 year ago

Tivic Health Extends its Worldwide License of TLR5 Agonist Entolimod to Include the Treatment of Neutropenia

Apr 10, 2025, 8:30 AM EDT - 1 year ago

Tivic Health Systems, Inc. Regains Compliance with NASDAQ Minimum Bid Price Listing Rule

Mar 21, 2025, 4:30 PM EDT - 1 year ago

Valion Bio Earnings Call Transcript: Q4 2024

Mar 21, 2025, 4:00 PM EDT - 1 year ago

Tivic Reports Year End 2024 Financial Results and Provides Overview of Strategy for Transformation and Growth

Mar 13, 2025, 4:59 PM EDT - 1 year ago

Tivic Health to Report 2024 Year-End Financial Results on March 21st Via Conference Call and Webcast

Mar 6, 2025, 8:15 AM EST - 1 year ago

Tivic Health and Feinstein Institute Present New Data Showing Personalized Vagus Nerve Stimulation Method Optimizes Impact on Autonomic Nervous System

Mar 5, 2025, 8:15 AM EST - 1 year ago

Tivic Health Systems, Inc. Announces Reverse Stock Split

Mar 3, 2025, 8:15 AM EST - 1 year ago

Tivic Health Files Patent For Optimized Electrical Stimulation of the Vagus Nerve

Feb 24, 2025, 8:15 AM EST - 1 year ago

Tivic Health Names Biotech Industry Veteran Michael K. Handley to Executive Leadership Team

Feb 12, 2025, 8:30 AM EST - 1 year ago

Tivic Health Acquires Exclusive Worldwide Rights to Phase III TLR5 Agonist from Statera Biopharma

Dec 23, 2024, 4:54 PM EST - 1 year ago

CEO Letter to Shareholders Issued by Tivic Health

Nov 14, 2024, 11:36 PM EST - 1 year ago

Tivic Reports Third Quarter 2024 Financial Results and Provides Business Update

Nov 14, 2024, 4:30 PM EST - 1 year ago

Valion Bio Earnings Call Transcript: Q3 2024

Nov 14, 2024, 8:45 AM EST - 1 year ago

Enrollment Complete in Tivic Health Optimization Study for its Non-Invasive Vagus Nerve Stimulation Device

Nov 12, 2024, 8:30 AM EST - 1 year ago

Tivic Health Validates European Patents in Great Britain, Germany, and France

Oct 15, 2024, 4:00 PM EDT - 1 year ago

Valion Bio Transcript: Maxim Group’s 2024 Healthcare Virtual Summit

Aug 14, 2024, 4:30 PM EDT - 1 year ago

Valion Bio Earnings Call Transcript: Q2 2024

May 15, 2024, 4:30 PM EDT - 2 years ago

Valion Bio Earnings Call Transcript: Q1 2024

Mar 25, 2024, 4:30 PM EDT - 2 years ago

Valion Bio Earnings Call Transcript: Q4 2023

Nov 14, 2023, 4:30 PM EST - 2 years ago

Valion Bio Earnings Call Transcript: Q3 2023

Aug 14, 2023, 4:30 PM EDT - 2 years ago

Valion Bio Earnings Call Transcript: Q2 2023

1.0.0